An open-label, fixed-sequence, two-part, two-period DDI study in healthy volunteer participants to determine the effect of futibatinib on P-gp and BCRP substrates (digoxin + rosuvastatin cocktail; Part 1) and the effect of a P-gp inhibitor (quinidine; Part 2) on futibatinib
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Digoxin (Primary) ; Futibatinib (Primary) ; Quinidine (Primary) ; Rosuvastatin (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 23 Jan 2025 New trial record